Survey Identifies Worry as a Core Symptom During Multiple Myeloma Treatment
A cross-sectional survey study sought to determine the core symptom experienced by patients with MM while undergoing chemotherapy treatment.
A cross-sectional survey study sought to determine the core symptom experienced by patients with MM while undergoing chemotherapy treatment.
Blacks and other race subgroups have higher multiple myeloma trial ineligibility rates compared with Whites.
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
However, multiple myeloma patients still have elevated likelihood of dying from nonmyeloma malignancies, CVDs.
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether a novel exercise app would be helpful for patients with multiple myeloma.
A phase 3, randomized study compared motixafortide with placebo to determine safety and efficacy of the drug in the mobilization of CD34+ HSPCs in patients with MM.
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
Researchers sought to determine whether genetic markers may indicate a high likelihood of benefitting from lenalidomide maintenance in patents with multiple myeloma who undergo ASCT.
Multiple myeloma patients aged 70 years or older have a nearly 3-fold higher rate of early death than younger patients, new research suggests.